<DOC>
	<DOCNO>NCT02927769</DOCNO>
	<brief_summary>The purpose study determine whether nivolumab + brentuximab vedotin , follow brentuximab vedotin + bendamustine participant suboptimal response , safe effective treatment classic Hodgkin lymphoma ( cHL ) child , adolescent , young adult failure first line therapy .</brief_summary>
	<brief_title>A Study Nivolumab + Brentuximab Vedotin Children , Adolescents , Young Adults With Classic Hodgkin Lymphoma ( cHL ) After Failure First Line Therapy , Followed Brentuximab Vedotin + Bendamustine Participants With Suboptimal Response</brief_title>
	<detailed_description />
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Classic Hodgkin Lymphoma ( cHL ) , relapse refractory Minimal limitation activity daily live measure Karnofsky ≥ 50 participant &gt; 16 year age Lansky ≥ 50 participant ≤ 16 year age . One prior anticancer therapy work Active , know , suspect autoimmune disease infection Active cerebral/meningeal disease relate underlying malignancy More one line anticancer therapy treatment Received stem cell transplant Hodgkin Lymphoma and/or solid organ transplant Prior treatment drug target T cell costimulation pathway ( checkpoint inhibitor ) Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>